Medifast Stock Earnings Estimates Boosted by Zacks Research

Medifast Inc (NYSE:MED – Free Report) – Equities researchers at Zacks Research upped their FY2026 earnings estimates for Medifast in a report issued on Monday, November 16th. Zacks Research analyst Team now forecasts that the specialty retailer will post earnings per share of ($0.52) for the year, up from their prior forecast of ($1.04). Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Medifast’s current full-year earnings is ($0.52) per share. Zacks Research also issued estimates for Medifast’s Q4 2026 earnings at $0.14 EPS, Q1 2027 earnings at ($0.20) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.56) EPS, Q1 2028 earnings at ($0.15) EPS, Q3 2028 earnings at ($0.33) EPS and FY2028 earnings at ($0.49) EPS.

Medifast (NYSE:MED – Get Free Report) last released its earnings results on Monday, October 26th. The specialty retailer reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.16. The firm had revenue of $72.05 million during the quarter, compared to the consensus estimate of $71.30 million. Medifast had a negative return on equity of 6.90% and a negative net margin of 13.64%.

Separately, Weiss Ratings lowered Medifast from a “sell (d)” rating to a “sell (d-)” rating in a report on Wednesday, October 28th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $12.00.

Check Out Our Latest Research Report on MED

Medifast Trading Down 1.1%

Shares of MED stock opened at $12.06 on Wednesday. Medifast has a 1 year low of $9.22 and a 1 year high of $13.63. The business’s fifty day moving average is $12.15 and its 200-day moving average is $11.41.

Institutional Investors Weigh In On Medifast

A number of large investors have recently made changes to their positions in MED. BlackRock Inc. purchased a new stake in Medifast in the 2nd quarter worth about $3,920,000. Marshall Wace LLP boosted its position in Medifast by 46.0% during the 3rd quarter. Marshall Wace LLP now owns 352,704 shares of the specialty retailer’s stock worth $4,063,000 after acquiring an additional 111,055 shares during the period. Bank of America Corp DE acquired a new stake in Medifast during the 2nd quarter worth about $924,000. Empowered Funds LLC purchased a new position in Medifast during the 2nd quarter valued at about $701,000. Finally, Great Lakes Advisors LLC purchased a new position in Medifast during the 2nd quarter valued at about $548,000. Institutional investors and hedge funds own 95.51% of the company’s stock.

Insiders Place Their Bets

In related news, Director Parsa Kiai acquired 43,150 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were purchased at an average price of $12.26 per share, for a total transaction of $529,019.00. Following the acquisition, the director owned 707,492 shares in the company, valued at approximately $8,673,851.92. This represents a 6.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Daniel R. Chard sold 9,545 shares of the company’s stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $11.98, for a total transaction of $114,349.10. Following the sale, the director directly owned 140,153 shares of the company’s stock, valued at $1,679,032.94. This represents a 6.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders purchased a total of 53,697 shares of company stock valued at $657,598 in the last quarter. 3.70% of the stock is currently owned by corporate insiders.

Medifast News Summary

Here’s some of the latest news about MED:

  • Positive Sentiment: Zacks Research raised its Q4 2026 EPS estimate to $0.14 from a loss of $0.17 and narrowed its FY2026 loss forecast to $0.52 per share from $1.04. These revisions suggest a better near-term outlook, though the full-year forecast still implies a loss. MarketBeat Medifast coverage
  • Positive Sentiment: Medifast is positioning its Trilivy nutrition and coaching program as a complement to GLP-1 weight-loss drugs, aiming to support sustainable weight management. This could offer a way to participate in the growing weight-loss treatment market, although commercial impact is not yet established. Can Medifast’s Coaching Model Complement GLP-1 Weight-Loss Drugs?
  • Neutral Sentiment: Zacks Research maintained a Hold rating. Its estimate changes indicate a mixed outlook rather than a clear analyst endorsement. MarketBeat Medifast coverage

About Medifast

(Get Free Report)

Medifast, Inc. is a health and wellness company focused on weight management and healthy living. Its products and programs are marketed primarily under the OPTAVIA brand. OPTAVIA offers structured plans that combine portion-controlled meal replacements and other nutrition products with guidance from independent coaches. The company’s approach emphasizes nutrition, behavior changes and ongoing support. Founded in 1980, Medifast serves customers primarily in the United States. Its business centers on selling products and connecting customers with coaches who provide support as they follow the company’s programs.

Featured Articles

Earnings History and Estimates for Medifast (NYSE:MED)

Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.